Compare Piramal Healthcare with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs NOVARTIS - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES NOVARTIS PIRAMAL ENTERPRISES/
NOVARTIS
 
P/E (TTM) x 15.8 544.2 2.9% View Chart
P/BV x 1.0 30.5 3.4% View Chart
Dividend Yield % 1.7 1.4 116.6%  

Financials

 PIRAMAL ENTERPRISES   NOVARTIS
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
NOVARTIS
Mar-19
PIRAMAL ENTERPRISES/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,303980 337.0%   
Low Rs1,797600 299.4%   
Sales per share (Unadj.) Rs716.5198.7 360.5%  
Earnings per share (Unadj.) Rs79.721.0 380.1%  
Cash flow per share (Unadj.) Rs107.922.3 484.8%  
Dividends per share (Unadj.) Rs28.0010.00 280.0%  
Dividend yield (eoy) %1.11.3 86.8%  
Book value per share (Unadj.) Rs1,477.5307.5 480.5%  
Shares outstanding (eoy) m184.4524.69 747.1%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.0 89.5%   
Avg P/E ratio x32.037.7 84.9%  
P/CF ratio (eoy) x23.635.5 66.6%  
Price / Book Value ratio x1.72.6 67.2%  
Dividend payout %35.147.7 73.7%   
Avg Mkt Cap Rs m470,29219,508 2,410.8%   
No. of employees `0007.80.6 1,346.0%   
Total wages/salary Rs m22,5041,171 1,921.6%   
Avg. sales/employee Rs Th16,899.48,445.4 200.1%   
Avg. wages/employee Rs Th2,877.72,015.7 142.8%   
Avg. net profit/employee Rs Th1,879.9891.0 211.0%   
INCOME DATA
Net Sales Rs m132,1534,907 2,693.3%  
Other income Rs m3,128783 399.7%   
Total revenues Rs m135,2815,689 2,377.8%   
Gross profit Rs m66,290123 53,981.8%  
Depreciation Rs m5,20232 16,356.9%   
Interest Rs m44,09716 277,342.1%   
Profit before tax Rs m20,119858 2,345.7%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,611340 2,532.7%   
Profit after tax Rs m14,701518 2,839.7%  
Gross profit margin %50.22.5 2,004.3%  
Effective tax rate %42.839.6 108.0%   
Net profit margin %11.110.6 105.4%  
BALANCE SHEET DATA
Current assets Rs m122,7428,055 1,523.9%   
Current liabilities Rs m310,8101,850 16,799.6%   
Net working cap to sales %-142.3126.4 -112.5%  
Current ratio x0.44.4 9.1%  
Inventory Days Days2345 51.2%  
Debtors Days Days3934 114.5%  
Net fixed assets Rs m116,904150 78,040.2%   
Share capital Rs m369123 298.9%   
"Free" reserves Rs m272,1617,469 3,644.1%   
Net worth Rs m272,5307,592 3,589.8%   
Long term debt Rs m270,1960-   
Total assets Rs m856,2619,824 8,715.7%  
Interest coverage x1.554.9 2.7%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.5 30.9%   
Return on assets %6.95.4 126.4%  
Return on equity %5.46.8 79.1%  
Return on capital %12.411.5 107.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20058 26,389.6%   
Fx outflow Rs m4,8891,326 368.6%   
Net fx Rs m10,312-1,269 -812.8%   
CASH FLOW
From Operations Rs m-115,975-1,943 5,969.5%  
From Investments Rs m-8,2652,742 -301.4%  
From Financial Activity Rs m107,525-298 -36,057.9%  
Net Cashflow Rs m-16,650501 -3,321.4%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.0 2.0 200.0%  
FIIs % 26.6 1.6 1,662.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 21.5 76.7%  
Shareholders   93,274 41,647 224.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Market Updates, IPO Buzz, and Top Cues in Focus Today(Pre-Open)

On Thursday, Indian share markets traded on a positive note throughout the day and ended higher.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (2QFY20); Net Profit Up 16.5% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 16.5% YoY). Sales on the other hand came in at Rs 36 bn (up 14.6% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 9, 2019 | Updated on Jul 9, 2019

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Dec 12, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS